| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 1 | +0.00% | +64.72% | +1.08% | +63.64% | +63.64% | — |
| 14d | 1 | +0.00% | +69.72% | -1.47% | +71.20% | +71.20% | — |
| 30d | 1 | +0.00% | +35.63% | -0.22% | +35.85% | +35.85% | — |
| 60d | 1 | +0.00% | +23.61% | -2.23% | +25.84% | +25.84% | — |
| 90d | 1 | +0.00% | +17.57% | -4.19% | +21.76% | +21.76% | — |
| 180d | 1 | +0.00% | +68.13% | +8.30% | +59.83% | +59.83% | — |
| 1y | 1(1 pending) | — | — | — | — | — | — |
| 2y | 1(1 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| GLUE MONTE ROSA THERAPEUTICS, INC. | SALE Chief Operating Officer | 2,175 | — | — | 31,298 | Jun 23, 2026 | Jun 25, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 2,175 | $20.00 | $43.5K | 62,371 | Jun 23, 2026 | Jun 25, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASE Chief Operating Officer | 2,175 | $3.98 | $8.7K | 64,546 | Jun 23, 2026 | Jun 25, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASE Chief Operating Officer | 2,176 | $3.98 | $8.7K | 64,547 | Jun 17, 2026 | Jun 18, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | SALE Chief Operating Officer | 2,176 | — | — | 33,473 | Jun 17, 2026 | Jun 18, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 2,176 | $19.00 | $41.3K | 62,371 | Jun 17, 2026 | Jun 18, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASE Chief Operating Officer | 2,175 | $3.98 | $8.7K | 64,546 | May 27, 2026 | May 28, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 2,175 | $20.00 | $43.5K | 62,371 | May 27, 2026 | May 28, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | SALE Chief Operating Officer | 2,175 | — | — | 35,649 | May 27, 2026 | May 28, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 2,176 | $19.00 | $41.3K | 62,371 | May 22, 2026 | May 26, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | SALE Chief Operating Officer | 2,176 | — | — | 37,824 | May 22, 2026 | May 26, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASE Chief Operating Officer | 2,176 | $3.98 | $8.7K | 64,547 | May 22, 2026 | May 26, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | SALE Chief Operating Officer | 2,629 | $15.17 | $39.9K | 62,371 | Jan 5, 2026 | Jan 5, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 35,000 | — | — | 65,000 | Jan 2, 2026 | Jan 5, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 158,000 | — | — | 158,000 | Jan 2, 2026 | Jan 5, 2026 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 30,000 | — | — | 30,000 | Jan 2, 2025 | Jan 6, 2025 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 135,000 | — | — | 135,000 | Jan 2, 2025 | Jan 6, 2025 ↗ | View → |
| GLUE MONTE ROSA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 40,000 | — | — | 40,000 | Jun 3, 2024 | Jun 5, 2024 ↗ | View → |